New targets for new therapeutic approaches

New targets for new therapeutic approaches

Because of its resistance profiles, Pseudomonas aeruginosa remains probably one of the challenging bacteria responsible for ventilator-associated pneumonia in the ICU. Nevertheless, a much better understanding of its mechanism of virulence, such as the type 3 secretion system that can also impact on resistance, gives some opportunities for management improvement. The most promising approach is ...

New Therapeutic Targets

Lupus 2014: New Targets, New Approaches

The protracted diagnostic period and variable disease presentation not only complicate diagnosing SLE but also the epidemiologic study of it. Coupled with the remitting and relapsing nature of the disease and the challenges in managing it, clinical research in lupus requires careful attention to study design, control selection, temporality, and many often overlooked issues in the analysis phase...

[Lymphangioleiomyomatosis: new therapeutic approaches].

Lymphangioleiomyomatosis (LAM) is a rare disease that affects young women of child-bearing age. It is characterized by the presence of cystic changes in the pulmonary parenchyma, repeated pneumothorax, chylothorax and renal angiomyolipomas, and in the majority of cases it is accompanied by a progressive loss in lung function.1 In the last two decades, there has been an increase in the understan...

MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?

Familial hypercholesterolemia (FH) is the most common inherited form of dyslipidemia and a major cause of premature cardiovascular disease. Management of FH mainly relies on the efficiency of treatments that reduce plasma low-density lipoprotein (LDL) cholesterol (LDL-C) concentrations. MicroRNAs (miRs) have been suggested as emerging regulators of plasma LDL-C concentrations. Notably, there is...